Author: admin

Market Brief: After Viking Therapeutics’ Results, Is Entera Bio the Oral Platform Play to Watch? (NASDAQ: ENTX)

Viking Therapeutics’ (Nasdaq: VKTX) 40% stock drop underscored the challenge in GLP-1 obesity drugs: balancing weight loss with tolerability. Its oral candidate required massive daily doses, driving high dropout rates. Entera Bio (Nasdaq: ENTX), with its N-Tab oral peptide platform, aims to solve this by enabling lower doses with better bioavailability. Despite a 400% run in 2024, Entera’s $86M valuation may create an entery point for investors seeking an under-the-radar oral platform play.

Viking Therapeutics’ (Nasdaq: VKTX) 40% stock crash this week revealed a fundamental problem plaguing the GLP-1 driven obesity movement: achieving meaningful weight loss while balancing tolerability to keep patients on these drugs long enough to improve their potential heart, diabetes, liver and other serious metabolic conditions. In developing its oral tablet format of VK2735, Viking essentially required a daily dose of 60-120mg to reach attractive weight loss (10-13% at 13 weeks), but this came with 28-38% of patients quitting treatment within just 13 weeks due to side effects.

This setback highlights why the oral peptide delivery market – potentially worth billions – remains largely unconquered despite massive pharmaceutical investment. The challenge isn’t just finding effective compounds; it’s developing oral delivery technology sophisticated enough to make them work at reasonable doses.

Enter Entera Bio (Nasdaq: ENTX), an $86 million biotech that has spent over a decade optimizing its proprietary oral peptide technology and platforms. N-Tab delivers a disruptive solution to oral peptide development and each of Entera’s pipeline candidates is customized to optimize patient outcomes. In comparison, even after the massive 40% drop, Viking still trades at a $2.8 billion market cap.

Entera focuses on transforming injectable peptide therapies into convenient daily tablets through its proprietary N-Tab platform. Entera’s oral peptide platform houses candidates targeting obesity/improvement of metabolic conditions, osteoporosis, and rare disorders such as hypoparathyroidism.

Why Entera’s Approach May Succeed Where Others Failed

For its obesity and metabolic program, Entera’s collaboration with OPKO Health (Nasdaq: OPK) has created a unique combination of proven compound, advanced platform, and potential for optimized dosing that addresses the core challenges Viking encountered.

Different API with Proven Human Efficacy: Entera’s oral obesity program combines OPKO’s proprietary long-acting oxyntomodulin analog (OPK-88006) with Entera’s N-Tab technology. OPKO previously demonstrated significant weight loss and cardioprotective effects in 420 obese and diabetic patients using weekly injections. At the June 2024 Endocrine Society meeting, Entera reported that oral OXM achieved target plasma concentrations with duration consistent with semaglutide (Rybelsus®), plus statistically significant glucose reduction in preclinical studies. IND filing expected early 2026.

Platform Technology is Everything: Viking’s crude approach required significant dosages with high dropout rates. Entera’s N-Tab platform uses sophisticated excipients tailored to each peptide, achieving optimized bioavailability in patient-friendly tablets.

PK Data Supports Low-Dose Efficacy: Entera’s IND-enabling PK studies demonstrated the potential for semaglutide (Rybelsus) – equivalent coverage at 25mg daily—5x lower than Viking’s 120mg strategy. This has huge implications for safety and tolerability – not to mention cost and patient access. This also further validates Entera’s N-Tab platform superiority.

The Valuation Disconnect – Multiple Billion-Dollar Markets in Play

The market opportunity in oral delivery has attracted serious pharmaceutical investment. Novo Nordisk paid $1.8 billion for Emisphere’s oral absorption technology (used in Rybelsus), while Merck committed up to $493 million for multiple early-stage oral peptide platform access.

Entera’s platform approach creates multiple shots on goal to transform medical markets. Their lead program, EB613, is advancing toward Phase 3 as the first potential oral peptide treatment for osteoporosis, addressing over 200 million women globally who currently face only injectable options. Entera just got a big win with FDA enabling the company to pursue its registrational study using a BMD endpoint in a single placebo controlled study—unprecedented to date and speaks to the strength of the program. In contrast to the obesity space, EB613 is first in class and the only oral peptide targeting the estimated $12 billion osteoporosis market.

Additionally, EB612, Entera’s program for hypoparathyroidism would be the first oral PTH hormone replacement for 60,000-115,000 U.S. patients, potentially disrupting Ascendis Pharma’s dominant position with recently launched Yorvipath which requires daily injections (Nasdaq: ASND).

Yet Entera trades at just $86 million – a fraction of Viking’s $2.8 billion market, and that’s after Viking’s 40% dive. Notably, while Entera’s stock ascended 400% in 2024, it seems to remain under the radar. The one Wall Street analyst covering the Company has issued a buy rating and a $10 price target, implying 400%+ potential upside. With the recent endpoint win for EB613 and plans to move oral OXM to the clinical phase next year, it appears the thesis may be starting to play out.

For investors seeking exposure to the next breakthrough in biotechnology, the answer may not lie in the companies making headlines, but in those quietly solving the fundamental challenges others can’t crack, before they hit the headlines.

 

This article was syndicated from NewzBlaze

 

Recent News Highlights from Entera:

Entera Bio Announces Second Quarter 2025 Financial Results and Business Updates

Entera Bio Receives FDA Agreement on BMD as Primary Endpoint for EB613 Registrational, Phase 3 Study in Post-Menopausal Women with Osteoporosis

 

 

Disclaimer & Disclosure: This content is a form of paid promotional content and advertising. Wall Street Wire has received cash compensation from Entera Bio Ltd for promotional media services provided on an ongoing subscription basis. This content is for informational purposes only and does not constitute financial advice. Wall Street Wire is not a broker-dealer or investment adviser. Full compensation details and information regarding the operator of Wall Street Wire are available wallstwire.ai/disclosures. We are not responsible for any price targets or market size figures that may be cited in this article nor do we endorse them, they are quoted based on publicly available news reports and additional price targets or figures may exist that may not have been quoted. This article should not be considered an official communication by the issuer.

Media Contact
Company Name: Wall Street Wire
Contact Person: Editorial Staff
Email: Send Email
Country: United States
Website: https://wallstwire.ai/

 

Press Release Distributed by ABNewswire.com
To view the original version on ABNewswire visit: Market Brief: After Viking Therapeutics’ Results, Is Entera Bio the Oral Platform Play to Watch? (NASDAQ: ENTX)

100% Bonus Depreciation Is Back – Here’s What That Means for Business Jet Buyers in 2025

100% Bonus Depreciation Is Back - Here’s What That Means for Business Jet Buyers in 2025

Big news for business owners and entrepreneurs: 100% bonus depreciation is back—and this time, it’s here to stay.

That’s right—buyers who finance or purchase a business aircraft in 2025 can now reduce their tax liability by writing off the entire cost of any business aircraft they acquire in the first year it’s put into service, as long as it’s used primarily for business. This tax break can mean major savings and a smarter way to invest in your company’s travel capabilities.

“Now that full bonus depreciation has been restored without a phase-out, buyers are in a great position to get a lot more out of their aircraft purchase,” says Susan Weeden, President of The Aircraft Lenders. “It’s a win-win: by acquiring a business aircraft, you get the tax benefit while making travel faster and easier. Financing your aircraft allows you to do so without tying up too much of your capital.”

The Aircraft Lenders partners with over 50 aviation lenders across the country to help clients lock in competitive financing tailored to their mission and financial profile. Whether you’re eyeing a turboprop, light jet, or large cabin aircraft, the right financing can help you get in the air faster while making the most of the tax incentives available.

With the return of 100% bonus depreciation and no sunset clause in sight, 2025 is shaping up to be a great time to take your business aviation plans to the next level.

About The Aircraft Lenders

The Aircraft Lenders is a boutique aircraft financing advisory firm that helps clients across the U.S. secure the best lending solutions for their aircraft purchases. With deep industry expertise and a hands-on approach, we make the financing process smooth, transparent, and tailored to your goals.

Want to explore your options? Visit www.theaircraftlenders.com and let’s talk about how aircraft financing can support your business and bottom line.

Disclaimer: Always consult your CPA or tax advisor to determine how bonus depreciation may apply to your specific situation. Need a referral to an aviation tax expert? Get in touch! We have a network of trusted advisors we can refer you to.

Media Contact
Company Name: The Aircraft Lenders
Email: Send Email
Phone: (973) 577-4226
Address:428 Upper Mountain Ave
City: Montclair
State: NJ
Country: United States
Website: https://theaircraftlenders.com/

Discovering the Next Wave of Biotech Innovation (MDCX, RNXT, JSPR, LSB)

The biotechnology sector is entering a dynamic growth phase, fueled by advances in gene therapy, AI-assisted drug discovery, and personalized medicine. Global biotech revenue is projected to grow from $1.55 trillion in 2024 to over $4.6 trillion by 2034, reflecting a surge in both investment and innovation. Venture funding is rebounding strongly, with billions pouring into early-stage companies developing transformative therapies.

For investors, this creates a unique opportunity: small-cap and emerging biotech firms are often operating under the radar, tackling complex medical challenges with innovative approaches. While larger pharmaceutical companies dominate headlines, these up-and-coming players have the potential to deliver outsized returns if their therapies succeed in clinical trials and gain regulatory approval. Staying ahead of the curve means identifying these companies before the market fully recognizes their potential. Here are a few small but promising biotech companies that investors should be keeping on their radar.

Medicus Pharma Ltd. (Nasdaq: MDCX) is a biotech and life sciences company focused on accelerating the clinical development of novel and disruptive therapeutic assets. The company operates across multiple countries and continents with a core strategy of advancing innovative treatments in oncology and beyond. Through its wholly owned subsidiary, SkinJect Inc., Medicus is pursuing the development of a noninvasive microneedle patch for basal cell carcinoma, the most common form of skin cancer. This investigational therapy, called D-MNA, delivers doxorubicin through dissolvable microneedles directly into tumor cells.

The D-MNA program has already shown promise in early-stage testing. In March 2021, a Phase 1 safety and tolerability study met its primary objective and reported complete responses in six participants based on histological examination. Building on that success, the company initiated its Phase 2 study, SKNJCT-003, which is now underway across nine clinical sites in the United States and additional locations in Europe and the United Arab Emirates. Interim analysis earlier this year suggested more than sixty percent clinical clearance among randomized patients, a signal of efficacy that has generated attention.

On August 21, Medicus Pharma Ltd. (Nasdaq: MDCX) announced a major milestone in this program. The United States Food and Drug Administration accepted the company’s Type C meeting request, a step that allows Medicus to formally engage with regulators on the clinical pathway for D-MNA. The company has already submitted its questions in writing and expects a response before the end of the third quarter. The stated goal is to secure FDA alignment that could fast-track development. In the same announcement, Medicus confirmed that SKNJCT-003 has now randomized more than seventy-five percent of the ninety patients targeted for enrollment. This level of progress indicates the trial is moving toward completion and will soon be in a position to generate pivotal data.

Management emphasized the importance of this regulatory step. Executive Chairman and Chief Executive Officer Dr. Raza Bokhari commented that “the fundamentals of the company are extremely strong today” and highlighted progress at SkinJect as well as strategic moves such as the pending acquisition of Antev, a UK-based biotech developing the GnRH antagonist Teverelix for advanced prostate cancer. In parallel, Medicus recently signed a memorandum of understanding with HelixNano, a Boston biotech with an advanced mRNA platform, to explore thermostable vaccines using Medicus’ microneedle technology.

Financially, the company ended the second quarter with $9.7 million in cash and cash equivalents, a significant increase from $4.0 million in the prior quarter, aided by $11.5 million in financing transactions and warrant exercises. Research and development spending continues to rise as trials expand, and the net loss widened to $6.2 million. However, insiders have exercised stock options and expressed their intent to hold, which the company views as a sign of confidence in future prospects.

Taken together, MDCX represents a small but ambitious clinical-stage biotech advancing a differentiated approach to cancer treatment. With the FDA now engaged and its Phase 2 program nearing full enrollment, the coming quarters could be highly consequential for the company and its investors.

RenovoRx, Inc. (Nasdaq: RNXT) is a small clinical-stage biotech company developing a new way to treat tough cancers, starting with pancreatic cancer. Its approach centers on a drug delivery system called RenovoCath, which uses the company’s Trans-Arterial Micro-Perfusion platform to deliver chemotherapy directly to a tumor through targeted blood vessels. By getting the drug exactly where it needs to go, the goal is to boost effectiveness while reducing side effects that come with systemic chemotherapy.

The lead program, known as TIGeR-PaC, is a Phase III trial testing RenovoCath with gemcitabine in patients with locally advanced pancreatic cancer, one of the hardest cancers to treat. In August, an independent committee reviewed interim results and recommended the study continue, which means there were no safety concerns and early signals were strong enough to warrant moving forward. If the trial proves successful, RNXT could be in position to address a large unmet need and open the door to broader use of its delivery platform in other cancers.

At the same time, RenovoRx is already generating early revenue from RenovoCath as a medical device on its own. In the second quarter of this year, the company reported more than $400,000 in revenue with adoption at 13 cancer centers, including top academic hospitals. This shows that doctors are beginning to see value in the device, even before a potential drug approval.

With $12.3 million in cash, RNXT believes it has enough resources to reach its next major trial milestone in 2026. If the Phase III data turn out well, the company could be looking at a sizable commercial opportunity in pancreatic cancer, with the added potential to expand into other solid tumors over time.

Jasper Therapeutics, Inc. (Nasdaq: JSPR) is a clinical-stage biotech company focused on developing targeted therapies for mast cell-driven diseases, including chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and asthma. The company’s lead asset, briquilimab, is a monoclonal antibody designed to block the KIT receptor, disrupting the survival signal for mast cells and helping to reduce the underlying source of inflammation. This targeted approach has the potential to provide durable symptom control while minimizing side effects commonly associated with broader treatments.

Briquilimab has already shown encouraging results in clinical studies. In the BEACON Phase 1b/2a trial for CSU, single doses in the 240 mg and 360 mg cohorts achieved complete responses in 89% of patients, with many seeing improvements within two weeks. In the open-label extension study, 73% of patients maintained a complete response at 12 weeks, while the SPOTLIGHT study in CIndU showed a 92% complete response rate. The drug has been well-tolerated, with few adverse events, none of which led to discontinuation. These results suggest that JSPR could become a highly differentiated therapy for patients who currently have limited options.

Recently, Jasper Therapeutics streamlined operations to focus on its urticaria programs and extend its cash runway, including halting other clinical programs and reducing its workforce by approximately 50%. This leaner structure positions the company to concentrate resources on advancing briquilimab through pivotal trials, including additional patient cohorts in BEACON and the planned Phase 2b CSU study expected to begin in mid-2026. With $39.5 million in cash as of June 2025, JSPR is financially equipped to continue development and deliver upcoming clinical readouts.

For investors, the combination of compelling efficacy data, a clear clinical focus, and a manageable cash burn profile highlights Jasper Therapeutics, Inc. (Nasdaq: JSPR) potential. Briquilimab could address significant unmet medical needs in chronic urticarias, and upcoming trial updates later this year may provide additional catalysts to support the company’s long-term growth prospects.

LakeShore Biopharma Co., Ltd. (Nasdaq: LSB) is a global biopharmaceutical company developing next-generation vaccines and therapeutic biologics for infectious diseases and cancer. The company leverages its proprietary PIKA immunomodulating platform to create novel preventive and therapeutic biologics targeting illnesses like rabies, hepatitis B, and influenza. Operating across China, Singapore, and the Philippines, LSB combines local expertise with global biopharma experience, positioning itself to capture growing demand in high-need markets.

Financially, LSB is showing signs of momentum. Fiscal Year 2025 revenue rose 7.2% year-over-year to RMB 615 million, with gross profit climbing 11.3% and gross margin improving to 82.5%. Operating expenses fell by 34.2% year-over-year, reflecting tighter cost management, while net loss narrowed dramatically to RMB 100 million, and adjusted net loss fell to RMB 40 million. These results demonstrate the company is steadily improving operational efficiency and moving toward a more sustainable financial profile. A recent $15 million private placement adds additional capital to fund R&D and commercialization efforts, giving LSB the resources to continue scaling its platform.

The company’s potential lies in its ability to translate the PIKA platform into commercially successful products. Vaccines and biologics remain high-demand areas, particularly in Asia where infectious disease prevention is a public health priority. LSB’s focus on both preventive and therapeutic biologics gives it a diversified pipeline that could generate multiple revenue streams if clinical programs succeed. Early signs of improved margins, controlled expenses, and a growing cash position suggest that the company could leverage its existing momentum to expand its market presence.

For investors, LSB represents a play on innovation in vaccines and biologics within emerging Asian markets. While still early in its growth trajectory, the combination of a differentiated technology platform, expanding commercial capabilities, and a more disciplined financial profile positions the company as a potential long-term opportunity in the global biopharma space.

Disclaimers: RazorPitch Inc. “RazorPitch” is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performances are not statements of historical fact and may be forward-looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated by Medicus Pharma to assist in the production and distribution of content related to MDCX. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only; you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third-party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content.

Media Contact
Company Name: RazorPitch
Contact Person: Mark McKelvie
Email: Send Email
City: NAPLES
State: Florida
Country: United States
Website: https://razorpitch.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Discovering the Next Wave of Biotech Innovation (MDCX, RNXT, JSPR, LSB)

Nurses On Calls, Inc. Launches Community Focused Staffing Enhancements

Nurses On Calls, Inc. Launches Community Focused Staffing Enhancements
Nurses On Calls, Inc. announces operational updates aimed at strengthening support for local healthcare facilities and caregiving environments. Through refined scheduling systems, enhanced training modules, and closer collaboration with partner providers, the company seeks to ensure dependable staffing coverage and smoother transitions across shifts.

Meeting Local Care Demands with Compassion

Growing patient needs and fluctuating census levels have prompted a deeper look at how staff placements are managed. Nurses On Calls, Inc. has implemented targeted recruitment and retention strategies designed to stabilize rosters and maintain continuity of care across long-term care homes. Emphasis remains on clinical competence, communication skills, and respectful bedside manner that families and care teams appreciate.

Flexible Options for Skilled Workforce Needs

To accommodate a variety of staffing scenarios, the organization expanded service tiers that include temporary placements, per diem coverage, and long-term assignments. Facilities looking for a reliable Nursing agency will find access to licensed nurses and certified aides with competencies. Scheduling coordinators match credentials to clinical demands, helping to reduce administrative burden and support clinical workflows.

Specialized Support for Nursing Assistants

Certified nursing assistants play an essential role in daily care routines and quality of life outcomes. The newly enhanced CNA staffing agency practice focuses on credential verification, ongoing competency checks, and tailored shift training to foster confidence in high turnover settings. This approach supports smoother handoffs during busy shifts.

Rapid Response for Short Staffing Episodes

Unexpected absences and sudden surges in demand require immediate solutions. The rapid deployment program known internally as the short call roster now provides quick coverage for brief gaps. Facilities seeking a Short in staff agency resource can request same-day placements when critical staffing shortages arise, with clinical leads confirming assignments before dispatch.

About Nurses On Calls, Inc.

Nurses On Calls, Inc. operates from Bolingbrook, Illinois, offering comprehensive caregiver placement, training support, and scheduling management for healthcare and in-home care providers. The company prioritizes safe staffing, professional development, and community engagement to support resilient local care networks.

Media Contact
Company Name: Nurses On Calls, Inc.
Contact Person: Jordan Malonga
Email: Send Email
Phone: (630)759-0069
Address:1475 Basswood Dr
City: Bolingbrook
State: IL
Country: United States
Website: https://www.nursesoncalls.com/

Droved Helps Local Businesses Win in the New Era of AI Search

“Droved logo”
Droved, a Local SEO and AI Search Optimization agency based in Toronto, helps service businesses across the United States and Canada, succeed in the age of AI-powered recommendations. With expertise in Google Maps SEO, Google Business Profile optimization, Generative Engine Optimization (GEO), and Local SEO for service businesses, Droved ensures clients stay visible across Google and AI platforms like ChatGPT, Gemini, Perplexity, and Claude.

Droved, a leading Local SEO agency specializing in AI search optimization, today announced new solutions designed to help service-based businesses thrive in the fast-changing digital landscape. By combining Local SEO best practices with advanced Generative Engine Optimization (GEO) strategies, Droved positions its clients to dominate visibility across Google Maps, Google Business Profile optimization, and emerging AI-powered platforms such as ChatGPT, Gemini, Perplexity, and Claude.

As consumer search behavior evolves, traditional SEO alone is no longer enough. Increasingly, customers rely on AI assistants and recommendation engines to make purchasing decisions, whether they’re booking a plumber, finding a lawyer, or hiring a local service provider. Droved bridges this gap by aligning businesses with the way AI systems process, rank, and recommend local providers.

“AI is redefining how people find and choose local businesses. Being visible on Google Maps is still critical, but now companies must also optimize for how AI assistants present recommendations,” said the founder of Droved. “That’s why we’ve built a model that blends Local SEO for service businesses with AI-powered local SEO strategies, ensuring our clients stay ahead.”

Winning Where It Matters Most

Droved’s approach focuses on three key pillars of visibility:

● Google Maps SEO & Business Profile Optimization: Ensuring businesses rank high in map packs and local results.

● Generative Engine Optimization (GEO): Crafting content and signals that AI engines use to recommend businesses.

● Industry-Focused Local SEO: Tailored campaigns for sectors such as home services, healthcare, legal, and more.

By mastering both traditional and AI-driven search ecosystems, Droved.com enables small and medium-sized businesses to establish trust, authority, and discoverability at every customer touchpoint.

Why This Matters Now

Industry experts estimate that by 2026, over 30% of online search queries will be handled directly by AI-driven assistants rather than traditional search engines. For service-based businesses, failure to adapt could mean disappearing from the places customers now rely on. Droved’s dual approach ensures that local companies are not only visible, but also chosen in these decision-making moments.

“We don’t just drive clicks; we drive calls, bookings, and customers,” added Droved.com founder. “Our mission is simple: make sure local businesses win in the new era of AI search.”

About Droved

Droved is a Toronto-based Local SEO agency specializing in AI-powered local SEO strategies and Generative Engine Optimization (GEO). The company helps USA and Canada service-based businesses maximize visibility across Google Maps, Google Business Profile, and leading AI assistants. With a focus on delivering measurable growth, Droved empowers local companies to thrive in today’s digital-first world.

Media Contact
Company Name: Droved
Contact Person: Albert
Email: Send Email
Country: Canada
Website: https://droved.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Droved Helps Local Businesses Win in the New Era of AI Search

Lindy Summers Series Delivers a Trio of Essential Reads for New Moms, Stay Tuned for an Exclusive Interview with Co-Author Marc Seffelaar

Co-Authors Lindy Summers and Marc Seffelaar Release Groundbreaking Trio of Books, Including “The Fourth Trimester,” Offering Real-World Advice for New Parents to Thrive, Not Just Survive

Parenting just got a little easier and a lot more supported. Authors Marc Seffelaar and Lindy Summers have teamed up to deliver a three-part parenting series that’s already capturing the hearts of new moms and caregivers around the world.

With The Fourth Trimester: The Simplest Baby Guide for a Healthy Baby and The New Mom, Lindy Summers and Marc Seffelaar bring a fresh, honest voice to the parenting world, one that feels personal, down-to-earth, and truly supportive.

Three Books, One Mission: Empower and Support Mothers Everywhere

The most recent from the three-part series is the most instrumental and hands-on of all three, on touching parents to give the real thing needed for those first very tender months of babyhood. The Fourth Trimester: The Simplest Baby Guide for Feeding A Healthy Baby and New Mom

➢ Graceful Journey: Creating Calm, Confident Connections with Your Baby

➢ Selfcare for New-Moms- A Gentle Approach to Self-Care and Early Childhood

➢ Each book looks at a different point of view regarding the early months of parenting-much but The Fourth Trimester is definitely the must-have book for all entering motherhood for the very first time.

While each book stands alone in its value, The Fourth Trimester – the newest in the series is quietly stealing the spotlight for all the right reasons.

A Book That Truly Gets What New Moms Go Through

The Fourth Trimester doesn’t throw around confusing terms or unrealistic rules. A refreshingly practical guide to newborns for new mothers, to keep their babies while still considering their own fortitude. This book takes you through everything important, from emotional transitions and physical recovery to baby care and relationship bonding, in a style that feels like a hand-holding partner, graciously available.

Written by Lindy Summers, a mom of five and a naturopathic doctor, alongside Marc Seffelaar, a dedicated wellness writer and father, the book comes from a place of real-life experience and sincere support. It’s not just informative, it’s reassuring.

Coming Soon: A Conversation with Marc Seffelaar

The coming weeks will present an opportunity for the readers to listen to Marc Seffelaar in an exclusive interview concerning the making of The Fourth Trimester with Lindy Summers and the personal thoughts that he brought into co-authoring this crucially important book.

The interview will further discuss Marc’s ideas for supporting fathers and partners in providing postpartum care; an issue very rarely discussed in this conversation but nevertheless essential.

Readers should keep their ears to the ground and subscribe for updates so as not to miss out on this truly rare and heavy-hearted talk.

More Like a Heart-to-Heart Than How-to

The Lindy Summers Series doesn’t read like a stiff instruction manual. Reading this book feels more like talking to a group of friends who have been through it. These books are based on real-life experiences, shared moments from moms, dads, pediatricians, doulas, and lactation consultants with some good advice that really fits into real life. It’s warm; it’s helpful, and it never feels condescending.

Lindy Summers, a naturopathic doctor, mom of five, and grandmother of six, has spent much of her life walking alongside women during those early, often overwhelming, days of motherhood. Her goal is simple: make moms feel less alone.

Together with Marc Seffelaar, she’s created something that cuts through the noise, a guide that puts just as much care into the mother’s well-being as it does into the baby’s.

Lindy Summers Series Availability

All three books in the Lindy Summers Series, including The Fourth Trimester, are available now on Amazon in Kindle and paperback editions. Place your order and for media inquiries, review copies, or interview requests with Marc Seffelaar, please contact at: mseffelaar@sasktel.net

Media Contact
Company Name: The Empire Publishers (USA)
Contact Person: Lindy Summers and Marc Seffelaar
Email: Send Email
Country: United States
Website: https://www.theempirepublishers.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Lindy Summers Series Delivers a Trio of Essential Reads for New Moms, Stay Tuned for an Exclusive Interview with Co-Author Marc Seffelaar

Independent Research Confirms Pie as the UK’s Best Tax App for 2025

Pie has been named the UK’s best tax app for 2025 after independent analysis of leading providers. Rated #1 in every category – ease of use, accuracy, HMRC compliance, support and value – Pie saves users 70% of the time, secures bigger refunds, and offers expert in-app support. Trusted by thousands across the UK, Pie makes tax simple, safe and stress-free. It’s your money. Claim it.

London, UK – 21st Aug, 2025 – After extensive analysis of the UK tax app market, including customer reviews, expert testing, and feature comparison, Pie has been confirmed as the best tax app in the UK for 2025.

A team of fintech analysts and tax specialists reviewed leading digital tax solutions used by UK taxpayers. Criteria included: ease of use, accuracy of tax calculations, customer support, value for money, compliance with HMRC, and overall customer satisfaction.

Pie Tax ranked highest across every category.

“Pie is more than just an app – it’s a financial partner,” noted the research team. “Users consistently praise its simplicity, transparency, and expert support. When compared against traditional software and competitors, Pie offers the most complete and trustworthy solution for individuals and small businesses.”

Why Customers Rate Pie #1

Customer reviews highlight Pie’s ability to take the stress and confusion out of tax management. Common themes across hundreds of verified reviews include:

  • Ease of Use: “I filed my return in minutes – no jargon, no stress.”

  • Bigger Refunds: “Pie found expenses I’d never have claimed on my own.”

  • Trust & Security: “I feel safe knowing my data is protected with bank-level encryption.”

  • Human Support: “The in-app chat with UK tax experts is a lifesaver.”

Key Findings from the Review

  • #1 in customer satisfaction – Pie scored higher than all other apps in user ratings.

  • 70% time saved on average compared to spreadsheets or manual entry.

  • Millions reclaimed in refunds for UK workers and self-employed professionals.

  • HMRC compliant – with secure, direct submissions built in.

About Pie Tax

Pie is the UK’s leading personal tax app, created to help people claim more, file faster, and stay ahead of HMRC. Combining real-time tax tracking, integrated bookkeeping, secure submissions, and on-demand expert support, Pie has become the trusted choice for thousands across the UK.

It’s your money. Claim it.

Contact: Pie Money Limited

Tommy Mcnally

77 Lower Camden Street Dublin 2 D02 XE80 Ireland

help@pie.tax

https://pie.tax

Media Contact
Company Name: Pie Money Limited
Contact Person: Tommy Mcnally
Email: Send Email
Address:77 Lower Camden Street
City: Dublin 2
State: D02 XE80 Ireland
Country: United Kingdom
Website: https://pie.tax

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Independent Research Confirms Pie as the UK’s Best Tax App for 2025

EasySMX Introduces S10 Game Controller – Tailored for Switch 2 Gamers With TMR Sticks, HD Rumble

Boulder, CO – EasySMX, the leading manufacturer of gaming peripherals, today announced the launch of the S10 Wireless Gaming Controller for Switch 2, engineered to bring premium, enriched features to Switch 2 gamers. At $59.99, the S10 combines pro-grade components and deep customization, redefining what a third-party controller can deliver.

EasySMX S10 is designed to deliver Switch 2 support, alongside professional-grade hardware upgrades such as TMR drift-free sticks, mechanical action buttons, and immersive HD rumble, solving both the compatibility gap and performance limitations in one go.

“The S10 represents our commitment to deliver a controller that fully leverages the capabilities of Switch 2,” said Robin, Product Manager at EasySMX. “Every feature, from system integration to mechanical precision, is tailored for serious Switch 2 players who demand excellence.”

S10 Unlocks More Fun for Switch 2 Gaming:

  • Optimized for Switch 2 Gamers: Purpose-built for the Switch 2, the S10 offers seamless compatibility with one-tap wake-up, a dedicated C button for in-game chat, enhanced motion controls, and built-in NFC for amiibo support.
  • Next-gen TMR Technology: The S10’s next-gen TMR (Tunnel Magnetoresistance) sticks combine high precision and extreme durability, backed by a solid 1000Hz polling rate for ultra-responsive gameplay. Plus, it also features a non-contact structure to ensure a smooth glide.
  • Full Mechanical Action Buttons: With premium structure of micro-switches, liquid silicone dampening, and enlarged keycaps, every press is faster, more consistent, and quieter click, giving gamers a more satisfying experience.
  • HD Rumble with ALPS Linear Motors: S10 uses high-fidelity ALPS linear motors to deliver multi-layered HD rumble—every explosion, crash, and combo comes alive in your hands.
  • Instant Customization for playstyles: Swap between circular and cross-shaped D-pads for optimal directional control. Refresh your look with magnetic faceplates and personalize your setup with smooth RGB lighting—all without tools.


Bonus Features That Complete the Experience

  • 2 mappable back buttons for pro-level control.
  • High-precision 6-axis motion sensing on Switch 2.
  • 1200mAh high-capacity battery for extended play sessions.
  • Multi-platform compatibility for Switch 2 & 1, PC, Android, and iOS.


Availability & Pricing

The EasySMX S10 is priced at $59.99 and available for order on 22/08/2025 exclusively through www.easysmx.com and select retail partners.

It will also be available later on Amazon, AliExpress, and other major platforms shortly after the official launch.

Get EasySMX S10 on EasySMX official website: https://www.easysmx.com/products/easysmx-s10-gaming-controller-for-switch-2-tmr-sticks-hd-rumble-motion-control

About EasySMX

EasySMX is a professional brand dedicated to gaming technologies and peripherals for over 9 years. With a commitment to innovation and quality, EasySMX has earned numerous BEST SELLER titles on Amazon, serving a global community of gaming enthusiasts.

Operating its own R&D Centre, Manufacturing Centre, and Consumer Research Centre, EasySMX continues to push the boundaries of gaming technology.

For more information about EasySMX, visit www.easysmx.com.

Media Contact
Company Name: EasySMX
Contact Person: Marketing Team
Email: Send Email
Country: China
Website: https://www.easysmx.com/

Moving Masters Brings Professional Office Moving Services to Downtown DC

Moving Masters Brings Professional Office Moving Services to Downtown DC
Moving Masters, a trusted Washington, D.C. commercial moving company, is now offering specialized office relocation services tailored for businesses in the heart of downtown D.C., ensuring efficient, secure, and minimally disruptive moves.

Hyattsville, MD – August 21, 2025 – Moving Masters, a leader in commercial moving solutions, offers professional office moving services to businesses in downtown Washington, D.C. With a focus on minimizing downtime and safeguarding assets, the company delivers complete relocation solutions designed for the fast-paced demands of the capital’s business district.

Known for its careful planning, secure handling, and commitment to customer satisfaction, Moving Masters offers a full suite of office moving services, including the relocation of office furniture, IT equipment, sensitive files, and specialized workspaces. Each move is managed by a team of experienced professionals trained to secure a smooth transition from start to finish.

By expanding services to downtown D.C., Moving Masters aims to meet the growing need for efficient, reliable, and secure office relocations among law firms, corporate offices, non-profit organizations, government agencies, and other professional institutions. Backed by extensive experience and the necessary clearances to handle sensitive and classified materials, their team is uniquely qualified to manage government relocations with precision and discretion. Their process is tailored to minimize operational disruptions, allowing clients to resume business quickly and confidently in their new location.

In addition to standard office moves, Moving Masters also provides secure transport for sensitive materials, expert furniture installation, and post-move support to ensure businesses are fully operational without delay.

Businesses in downtown Washington, D.C. seeking dependable office relocation services can now benefit from Moving Masters’ decades of experience, proven logistics expertise, and unmatched commitment to service excellence.

To learn more about Moving Masters’ office moving services or to request a quote, visit https://www.movingmasters.com or call (301) 278-8988.

Media Contact
Company Name: Moving Masters
Contact Person: Alex Klemko
Email: Send Email
Phone: +13012788988
Address:4900 Frolich Lane
City: Hyattsville
State: MD
Country: United States
Website: https://www.movingmasters.com

Europe Garage Door Market Volume to Surge to 2.36 Million Units by 2030 as EU Housing Plan Adds 1.2 Million Homes Across 15 Major Urban Areas – Arizton

“Europe Garage Door Market Research Report by Arizton”
Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast 2025–2030.

According to Arizton latest research report, Europe garage door market is growing at a CAGR of 3.10% during 2024-2030.

 

Looking for More Information? Click: https://www.arizton.com/market-reports/europe-garage-doors-market

 

Report Scope:

MARKET SIZE – REVENUE (2030): USD 3.20 Billion

MARKET SIZE – REVENUE (2024): USD 2.66 Billion

CAGR – REVENUE (2024-2030): 3.10%

MARKET SIZE – VOLUME (2030): 2.36 Million Units

HISTORIC YEAR: 2021-2023

BASE YEAR: 2024

FORECAST YEAR: 2025-2030

MARKET SEGMENTATION: Product Type, Material, Operation, End User, and Geography

GEOGRAPHIC ANALYSIS: North America, Europe, APAC, Latin America, and Middle East & Africa

 

Energy-Efficient Garage Doors: Europe Unexpected Sustainability Icon

The Europe garage door market is witnessing a strong shift toward energy-efficient solutions, as sustainability and energy conservation become central to construction and home improvement practices. Insulated garage doors with polyurethane or polystyrene cores and advanced weather sealing are emerging as the preferred choice, reducing heat transfer, stabilizing indoor temperatures, and lowering household energy costs.

Manufacturers such as Novoferm, with innovations like the ISO 45 Premium Plus sectional door, are aligning products with the region’s environmental objectives by combining thermal efficiency, modern aesthetics, security, and noise reduction. This positions energy-efficient garage doors not only as a sustainability-driven necessity but also as a premium lifestyle upgrade in Europe’s evolving residential market.

 

Key Developments in the European Garage Door Market

  • In April 2023, Novoferm advanced its smart integration strategy by launching a new Wi-Fi module for sectional garage doors, enabling seamless connectivity with smart home systems via a mini-USB interface.

  • In 2024, Teckentrup GmbH strengthened its European footprint by acquiring full ownership of Teckentrup UK Limited and ABC Industrial Doors Limited. This transition from joint ownership to a wholly owned subsidiary structure consolidated operational control and aligned strategic direction across its regional operations.

 

39% of UK Homes Are Smart: Garage Doors Join the Automation Wave

Smart technology integration is transforming the next phase of growth in the European garage door market, as consumers increasingly prioritize convenience, automation, and security. Leading manufacturers such as Novoferm are setting the pace with Wi-Fi modules that integrate seamlessly with Amazon Alexa, Google Home, and mediola, enabling centralized voice and app-based control. Complementary solutions from Homematic IP, Delta Dore, and retrofit devices like i-smartgate extend adoption by offering remote operation, lighting control, real-time monitoring, and smart upgrades for traditional systems.

With 39% of UK households already using smart home technologies, Europe is rapidly shifting toward modular, upgrade-ready garage door systems. This evolution not only strengthens interoperability and system efficiency but also positions the market for sustained expansion as garage doors become a critical part of the connected home ecosystem.

 

The Hidden Opportunity Behind Europe 1.6%–15% Housing Shortage

Europe housing shortage is becoming a structural driver of growth in the garage door market. In countries such as Germany, Ireland, Slovakia, Poland, Sweden, Spain, and the Netherlands, where shortages range from 1.6% to 15% of housing stock, large-scale residential expansion is creating steady downstream demand for essential building components, including garage doors. Every new housing unit, whether part of high-density urban projects with underground parking or suburban estates with detached garages, translates into fresh installation opportunities.

This surge is boosting volumes and accelerating demand for smarter, energy-efficient, and durable solutions. National initiatives, from the Netherlands’ plan to build 900,000 homes by 2030 to the UK’s £16 billion National Housing Bank, are opening long-term growth channels, making garage doors a central element of Europe’s evolving housing ecosystem.

 

UK Leads Market with USD 533M Revenue, Poland Surges Ahead

In 2024, the UK led Europe’s garage door market with revenue exceeding USD 533 million , driven by steady replacement demand, ongoing housing construction, and variable weather that boosts the need for durable, weather-resistant doors. Insulated sectional and corrosion-resistant models are gaining popularity for enhanced thermal performance and longevity.

Poland, while smaller in revenue, is projected to grow fastest in volume (CAGR >2%) thanks to expanding residential stock and infrastructure modernization. France, in contrast, shows the slowest growth among major European markets, highlighting regional differences in demand and market dynamics.

 

Book the Free Sample @: https://www.arizton.com/market-reports/europe-garage-doors-market

 

Key Company Profiles

  • Hörmann

  • Novoferm GmbH

  • Teckentrup UK Limited

  • Garador Ltd

  • ASSA ABLOY

Other Prominent Company Profiles

  • AlluGuard

  • Alulux GmbH

  • Birkdale

  • Cedar Door

  • ERREKA

  • Gliderol Garage Doors

  • KRUŽÍK s.r.o.

  • Rundum Meir

  • RYTERNA

  • Silvelox Group SpA

  • Käuferle GmbH & Co. KG

  • SWS

  • DoorHan Group Of Companies

  • Raynor Garage Doors

  • ROMA KG

 

Market Segmentation & Forecast

Product Type

  • Sectional

  • Roller

  • Up and Over

  • Side Hinged

  • Side Sliding

Material

  • Metal

  • Wood

  • Fiberglass

  • Others

Operation

  • Manual

  • Automatic

End User

  • Residential

  • Commercial

Geography

Europe

  • United Kingdom

  • Germany

  • France

  • Italy

  • Nordic

  • Benelux

  • Spain

  • Poland

 

Other Related Reports that Might be of Your Business Requirement    

Automatic Garage Door Operator Market – Global Outlook & Forecast 2023-2028

https://www.arizton.com/market-reports/automatic-garage-door-operator-market

Europe Doors and Windows Market – Industry Outlook & Forecast 2024-2029

https://www.arizton.com/market-reports/europe-door-and-window-market

 

What Key Findings Will Our Research Analysis Reveal?    

  • How big is the Europe garage door market?

  • What is the growth rate of the Europe garage door market?

  • Which region dominates the Europe garage door market share?

  • Who are the key players in the Europe garage door market?

  • What are the significant trends in the European garage door industry?

 

Why Arizton?                                               

100% Customer Satisfaction                                               

24×7 availability – we are always there when you need us                                               

200+ Fortune 500 Companies trust Arizton’s report                                               

80% of our reports are exclusive and first in the industry                                               

100% more data and analysis                                               

1500+ reports published till date                             

                  

Post-Purchase Benefit                                           

  • 1hr of free analyst discussion                                           

  • 10% off on customization                        

                 

About Us:                                                                                    

Arizton Advisory and Intelligence is an innovative and quality-driven firm that offers cutting-edge research solutions to clients worldwide. We excel in providing comprehensive market intelligence reports and advisory and consulting services.

We offer comprehensive market research reports on consumer goods & retail technology, automotive and mobility, smart tech, healthcare, life sciences, industrial machinery, chemicals, materials, I.T. and media, logistics, and packaging. These reports contain detailed industry analysis, market size, share, growth drivers, and trend forecasts.

Arizton comprises a team of exuberant and well-experienced analysts who have mastered generating incisive reports. Our specialist analysts possess exemplary skills in market research. We train our team in advanced research practices, techniques, and ethics to outperform in fabricating impregnable research reports.

Media Contact
Company Name: Arizton Advisory & Intelligence
Contact Person: Jessica
Email: Send Email
Phone: +1 3122332770
Country: United States
Website: https://www.arizton.com/market-reports/europe-garage-doors-market

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Europe Garage Door Market Volume to Surge to 2.36 Million Units by 2030 as EU Housing Plan Adds 1.2 Million Homes Across 15 Major Urban Areas – Arizton